Formulation and Characterization of Ciclopirox Olamine Mucoadhesive Effervescent Tablets for Vaginal Delivery

DOI:

https://doi.org/10.37285/ijpsn.2012.5.4.11

Authors

  • Milan R Rachh
  • B S Barot
  • B S Parejiya
  • P K Shelat
  • S S Deshpande

Abstract

The study was aimed to design and evaluate a new effervescent mucoadhesive vaginal drug delivery system for ciclopirox olamine (CPO), a broad-spectrum antifungal, antibacterial, and anti-inflammatory agent for effective treatment in vaginal candidiosis. Various polymers like Polyox 303, Carbopol 974P, HPMC K4M, Sodium CMC, HPC, Sodium Alginate, Xanthan Gum, Polycarbophil and Chitosan were used in the formulation of CPO effervescent mucoadhesive vaginal tablet (EMVT) employing direct compression as a method of preparation. The effervescent mixture (citric acid and sodium bicarbonate) was incorporated into the formulations to aid quick wetting and mucoadhesion of tablet followed by drug release modulation. The amount of polymer blends and effervescent mixture was optimized using 32 full factorial design. The swelling, mucoadhesive strength and in-vitro release were studied as dependent responses. The ex-vivo mucoadhesion was determined by modified mucoadhesion assembly. The ex-vivo residence test was carried out by modified USP dissolution test apparatus. In vitro anti-fungal activity of the CPO EMVT was determined in comparison to Candid®-V3 tablet. A good sustained effect and a moderate mucoadhesion (0.31N to 0.67N) were obtained with tablets containing HPMC K4M: Polyox 303 (1:1.4) and effervescent mixture (1:3). Ex-vivo mucoadhesion time of all the formulations was in the range of 8 to 24 h. The effervescent CPO tablet showed significantly higher in-vitro antifungal activity as compare to Candid®-V3 tablet (p< 0.05). The results of short term stability revealed stable characteristics of optimized formulation.  The proposed formulation may provide a potential antifungal activity against Candida albicans.

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Mucoadhesive polymers, vaginal candidiosis, effervescent, C.albicans.

Downloads

Published

2013-02-28

How to Cite

1.
Rachh MR, Barot BS, Parejiya BS, Shelat PK, Deshpande SS. Formulation and Characterization of Ciclopirox Olamine Mucoadhesive Effervescent Tablets for Vaginal Delivery. Scopus Indexed [Internet]. 2013 Feb. 28 [cited 2024 May 23];5(4):1902-1. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/600

Issue

Vol. 5 No. 4: January-March 2013

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Alam MA, Ahmad FJ, Khan ZI, Khar RK and Ali M (2007). Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS PharmSciTech 8: E109.

Bottenberg P, Cleymaet R, de Muynck C, Remon JP, Coomans D, Michotte Y and Slop D (1991). Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol 43: 457-464.

Carrillo-Munoz AJ, Brio S, Alonso R, del Valle O, Santos P and Quindos G (2002). Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates. Int J Antimicrob Agents 20: 375-379.

Ferrer J (2000). Vaginal candidosis: epidemiological and etiological factors. Int J Gynaecol Obstet 71 Suppl 1: S21-27.

Garg S, Vermani K, Garg A, Anderson RA, Rencher WB and Zaneveld LJ (2005). Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 22: 584-595.

Gurny R, Meyer JM and Peppas NA (1984). Bioadhesive intraoral release systems: design, testing and analysis. Biomaterials 5: 336-340.

Gursoy A, Sohtorik I, Uyanik N and Peppas NA (1989). Mucoadhesive controlled release systems for vaginal delivery. STP Pharma 5: 886-892.

Karasulu HY, Hilmioglu S, Metin DY and Guneri T (2004). Efficacy of a new ketoconazole bioadhesive vaginal tablet on candida albicans. Farmaco 59: 163-167.

Karasulu HY, Taneri F, Sanal E, Guneri T and Ertan G (2002). Sustained release bioadhesive effervescent ketoconazole microcapsules tabletted for vaginal delivery. J Microencapsul 19: 357-362.

Kast CE, Valenta C, Leopold M and Bernkop-Schnurch A (2002). Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J Control Release 81: 347-354.

Korsmeyer RW, Gurny R, Doelker E, Buri P and Peppas NA (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15: 25-35.

Lachman L, Lieberman LI and Kanig JL (1999). The theory and practice of industrial pharmacy, 4th Ed. Mumbai: Varghese Publishing House.

Mendenhall W and Sincich T. (1993). Regression analysis. in: A second course in business statistics: regression analysis, 4th Ed. San Francisco: Prentice Hall College Div.

Nafee NA, Ismail FA, Boraie NA and Mortada LM (2004). Mucoadhesive delivery systems. I. Evaluation of mucoadhesive polymers for buccal tablet formulation. Drug Dev Ind Pharm 30: 985-993.

Owen DH and Katz DF (1999). A vaginal fluid simulant. Contraception 59: 91-95.

Prashanth B, Swamy P, Areefulla S, Shirsand S and Gandra S (2007). Orodispersible tablets of meloxicam using disintegrant blends for improved efficacy. Ind J Pharm Sci 69: 836-840.

Sharma G, Jain S, Tiwary AK and Kaur G (2006). Once daily bioadhesive vaginal clotrimazole tablets: design and evaluation. Acta Pharm 56: 337-345.

Wang L and Tang X (2008). A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and 'in vivo' evaluation. Int J Pharm 350: 181-187.

Woodley J (2001). Bioadhesion: new possibilities for drug administration. Clin Pharmacokinet 40: 77-84.